Citations

Showing 10 of 108104 citations.

Vitamin C Plasma Levels Associated with Inflammatory Biomarkers, CRP and RDW: Results from the NHANES 2003–2006 Surveys
Crook, Jennifer , Horgas, Ann L. , Yoon, Saunjoo L. , Grundmann, Oliver , Johnson‐Mallard, Versie, Crook, Jennifer Marie, Yoon, Saun-Joo

Mayo Clinic

Nutrients | March 16, 2022 | Volume: 14 | Issue: 6 | Pages: 1254

10.3390/nu14061254 | PMID 35334908 Get It

Although undisputed for its anti-inflammatory and immune system boosting properties, vitamin C remains an inconsistently investigated nutrient in the United States. However, subclinical inadequacies may partly explain increased inflammation and decreased immune function within the population. This secondary analysis cross-sectional study used the 2003–2006 NHANES surveys to identify more clearly the association between plasma vitamin C and clinical biomarkers of acute and chronic inflammation C-reactive protein (CRP) and red cell distribution width (RDW). From plasma vitamin C levels separated into five defined categories (deficiency, hypovitaminosis, inadequate, adequate, and saturating), ANOVA tests identified significant differences in means in all insufficient vitamin C categories (deficiency, hypovitaminosis, and inadequate) and both CRP and RDW in 7607 study participants. There were also statistically significant differences in means between sufficient plasma vitamin C levels (adequate and saturating categories) and CRP. Significant differences were not identified between adequate and saturating plasma vitamin C levels and RDW. Although inadequate levels of vitamin C may not exhibit overt signs or symptoms of deficiency, differences in mean levels identified between inflammatory biomarkers suggest a closer examination of those considered at risk for inflammatory-driven diseases. Likewise, the subclinical levels of inflammation presented in this study provide evidence to support ranges for further clinical inflammation surveillance.
Exosomes for Regulation of Immune Responses and Immunotherapy
Hussain, Md Walid Akram , Jahangir, Sarah , Ghosh, Bikona , Yesmin, Farjana, Anis, Afnan , Satil, Sabikun Nahar, Anwar, Faizan , Rashid, Mohammad H.

Mayo Clinic

Journal of Nanotheranostics | March 16, 2022 | Volume: 3 | Issue: 1 | Pages: 55-85

10.3390/jnt3010005 Get It

Exosomes are membrane-enveloped nanosized (30–150 nm) extracellular vesicles of endosomal origin produced by almost all cell types and encompass a multitude of functioning biomolecules. Exosomes have been considered crucial players of cell-to-cell communication in physiological and pathological conditions. Accumulating evidence suggests that exosomes can modulate the immune system by delivering a plethora of signals that can either stimulate or suppress immune responses, which have potential applications as immunotherapies for cancer and autoimmune diseases. Here, we discuss the current knowledge about the active biomolecular components of exosomes that contribute to exosomal function in modulating different immune cells and also how these immune cell-derived exosomes play critical roles in immune responses. We further discuss the translational potential of engineered exosomes as immunotherapeutic agents with their advantages over conventional nanocarriers for drug delivery and ongoing clinical trials.
Electrodiagnostic Characteristics Suggestive of Muscle-Specific Kinase Myasthenia Gravis
Skolka, Michael , Lamb, Christopher J. , Rubin, Devon I., Laughlin, Ruple S. , Laughlin, Ruple S , Lamb, Christopher J , Skolka, Michael P , Klein, Christopher J.

Mayo Clinic

Neurology Clinical Practice | March 16, 2022 | Volume: 12 | Issue: 3 | Pages: 211-217

10.1212/cpj.0000000000001166 | PMID 35747537 Get It

Reply to A. Rizzo et al
Gile, Jennifer , Jatoi, Amina, Wee, Wen , Borad, Mitesh J. , Tran, Nguyen H. , Jatoi, Aminah , Ma, Wen Wee , Borad, Mitesh J , Gile, Jennifer Jane , Tran, Nguyen

Mayo Clinic

JCO Precision Oncology | March 16, 2022 | Volume: No volume available | Issue: 6 | Pages: No page available

10.1200/po.22.00061 | PMID 35294225 Get It

Transforming Nuclear Medicine with Nanoradiopharmaceuticals
Roy, Indrajit , Zavestovskaya, I. N. , Prasad, Paras N. , Prasad, Paras N , Krishnan, Sunil , Kabashin, Andrei V.

Mayo Clinic

ACS Nano | March 16, 2022 | Volume: 16 | Issue: 4 | Pages: 5036-5061

10.1021/acsnano.1c10550 | PMID 35294165 Get It

Interactive effects of apneic and baroreflex stress on neuronal coding strategies in human muscle sympathetic nerve activity
Kulas, Bartek , Klassen, Stephen A. , Moir, M. Erin , Shoemaker, J. Kevin , Shoemaker, J Kevin , Klassen, Stephen A

Mayo Clinic

Journal of Neurophysiology | March 16, 2022 | Volume: 127 | Issue: 4 | Pages: 1086-1097

10.1152/jn.00395.2021 | PMID 35294276 Get It

Discrete physiological stressors differentially affect sympathetic postganglionic neuronal rate-, population-, and temporal-coding strategies. When performing end-expiratory apnea (APN) during graded baroreflex unloading via lower body negative pressure (LBNP): 1) augmented sympathetic neuronal firing probability, 2) recruited larger and previously silent sympathetic postganglionic neurons at ambient and −10 mmHg, but not −40 mmHg LBNP, and 3) reduced neuronal discharge latency similarly across all conditions, independent of the level of baroreflex unloading.
Expert Consensus Guidelines for Assessing Students on the Social Determinants of Health
Mangold, Karen , Williams, Anna-leila , Ngongo, Wivine, Liveris, Marissa , Brown, Amy E. Caruso , Adler, Mark , Campbell, Mobola , Mangold, Karen A

Mayo Clinic

Teaching and Learning in Medicine | March 16, 2022 | Volume: 35 | Issue: 3 | Pages: 256-264

10.1080/10401334.2022.2045490 | PMID 35294293 Get It

Obesity is Associated With Myelin Oligodendrocyte Glycoprotein Antibody Associated Disease in Acute Optic Neuritis
Blum, Karni, Tiosano, Alon , Hellmann, Mark A. , Wilf‐Yarkoni, Adi , Bialer, Omer , Bhatti, M. Tariq, Schmitz‐Hübsch, Tanja , Friedemann, Paul, Stiebel‐Kalish, Hadas , Rubarth, Kerstin , Lotan, Itay , Flanagan, Eoin P. , Pittock, Sean J. , Asseyer, Susanna , Chen, John J.

Mayo Clinic

No container title available | March 16, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1411863/v1 Get It

Abstract Background: Optic neuritis (ON) is a frequent presentation of multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein-antibody disease (MOGAD) at onset. The pathophysiology underlying these diseases, especially MOGAD, is still being elucidated. While obesity has been reported to potentially be a risk factor for MS, this has not been explored in NMOSD or MOGAD. We aimed to investigate a possible association between obesity (body mass index [BMI] >30 kg/m²) and patients with MOGAD, NMOSD or MS. Methods: Multicenter non-interventional retrospective data collection from a first ever demyelinating attack of ON in patients subsequently diagnosed with MOGAD, NMOSD or MS between 2005-2020. The following data was collected: age, gender, ethnicity, BMI at disease onset and the etiology of ON after diagnostic work-up. A mixed model analysis was performed to assess the ability of obesity or BMI to predict MOGAD-ON and distinguish MOGAD-ON from NMOSD- and MS-ON. Main outcome measures included BMI in patients with acute ON and subsequent diagnosis of MOGAD, NMOSD or MS. Results: One-hundred and eighty-three patients were included: 44 with MOGAD, 49 with NMOSD, and 90 with MS. A higher BMI was significantly associated with a diagnosis of MOGAD-ON (p<0.001); in MOGAD patients the mean BMI was 31.6 kg/m² (standard deviation (SD) 7.2), while the mean BMI was 24.7 kg/m² (SD 5.3) in NMOSD patients and 26.9 kg/m² (SD 6.2) in MS patients. Mixed effects multionimal logistic regression, adjusted for age and gender with obesity as a binary variable revealed that obesity was associated with a higher odds ratio (OR) of a subsequent MOGAD diagnosis (OR 5.466, 95% CI: [2.039, 14.650], p = 0.001) in contradistinction with NMOSD. Conclusion: This study suggests an association between obesity and MOGAD. Our finding requires further exploration, but could have significant pathophysiologic implications if confirmed in larger prospective studies.
Failed Performance on the Test of Memory Malingering and Misdiagnosis in Individuals with Early-Onset Dysexecutive Alzheimer’s Disease
Corriveau‐Lecavalier, Nick , Alden, Eva , Alden, Eva C, Stricker, Nikki H. , Corriveau-Lecavalier, Nick , Machulda, Mary M. , Jones, David T.

Mayo Clinic

Archives of Clinical Neuropsychology | March 16, 2022 | Volume: 37 | Issue: 6 | Pages: 1199-1207

10.1093/arclin/acac016 | PMID 35435228 Get It

Abstract Objective Individuals with early-onset dysexecutive Alzheimer’s disease (dAD) have high rates of failed performance validity testing (PVT), which can lead to symptom misinterpretation and misdiagnosis. Method The aim of this retrospective study is to evaluate rates of failure on a common PVT, the test of memory malingering (TOMM), in a sample of clinical patients with biomarker-confirmed early-onset dAD who completed neuropsychological testing. Results We identified seventeen patients with an average age of symptom onset at 52.25 years old. Nearly fifty percent of patients performed below recommended cut-offs on Trials 1 and 2 of the TOMM. Four of six patients who completed outside neuropsychological testing were misdiagnosed with alternative etiologies to explain their symptomatology, with two of these patients’ performances deemed unreliable based on the TOMM. Conclusions Low scores on the TOMM should be interpreted in light of contextual and optimally biological information and do not necessarily rule out a neurodegenerative etiology.